Corporate Overview

Corporate Overview

Fractyl is applying unparalleled insights into intestinal biology to advance treatments and potential cures for metabolic diseases.

At Fractyl, we are applying new scientific insights in intestinal biology to advance treatments and potential cures for metabolic diseases.

Our growing product pipeline leverages our minimally invasive procedural therapy, Revita™ DMR (duodenal mucosal resurfacing), which is designed to rejuvenate the lining of the duodenum and improve patient health. We are currently advancing global clinical development of Revita DMR, initially targeting patients with conditions resulting from insulin resistance, including type 2 diabetes (T2D), nonalcoholic steatohepatitis (NASH), and polycystic ovarian syndrome (PCOS), while also exploring use of Revita DMR in combination with cell and gene therapy.

We believe our breakthrough insights offer the potential to restore health to millions of patients worldwide and reduce the global economic burden of metabolic disease. We are steadfast in our commitment to creating solutions for all of our partners seeking new treatment options, efficient and cost-effective care, and better outcomes.

Fractyl is a privately held company headquartered in Lexington, Massachusetts.


Our leadership team is channeling its collective expertise and past successes to advance life-changing treatments for patients with metabolic disease. Through our accomplished, Board of Directors, investors, and scientific advisors, we have access to some of the most insightful global industry and scientific minds.

Management Team

Harith Rajagopalan, MD, PhD
Harith Rajagopalan, MD, PhD

Co-Founder and CEO

Jay Caplan
Jay Caplan

Co-Founder and President

Margaret Borys
Margaret Borys

Chief Commercial Officer

Lisa Davidson
Lisa Davidson

Chief Financial Officer

Jon Fitzgerald
Jon Fitzgerald

Vice President of Quality Assurance and Regulatory Affairs

Juan Carlos Lopez-Talavera, MD, PhD
Juan Carlos Lopez-Talavera, MD, PhD

Len Rosberg
Len Rosberg

Vice President of Manufacturing


Harith Rajagopalan, M.D., Ph.D., is Co-founder and CEO of Fractyl, having started the company while serving as an Entrepreneur-in-Residence at General Catalyst Partners.

Prior to founding Fractyl, Harith was an academic cardiologist and physician-scientist. He received his B.S. in chemistry from Stanford University and went on to obtain M.D. and Ph.D. degrees from Johns Hopkins School of Medicine. At Johns Hopkins, Harith did groundbreaking and award-winning research on intestinal cancers that was published in top medical journals, including Nature and Science.

After medical school, Harith trained in internal medicine and clinical cardiology at Brigham and Women’s Hospital and completed a research fellowship at the Harvard Stem Cell Institute at Harvard Medical School.


Jay Caplan is Co-founder and President of Fractyl and has held leadership positions in the medical device field for more than twenty years.

Prior to founding Fractyl, Jay was the Chief Operating Officer of the Candela Corporation, a world leader in aesthetic devices. Previously, he was Chief Technology Officer and Vice President of Research and Development of InfraReDx, Inc. a venture-backed startup developing a novel cardiovascular imaging system to identify lipid-rich coronary plaques.

Prior to InfraReDx, Jay was Vice President Operations for Thermo Cardiosystems, where he led the team developing the HeartMate II left ventricular assist device. Jay holds a B.S. in electrical engineering from M.I.T. and an MBA from The Wharton School.


Margaret Borys is Chief Commercial Officer of Fractyl. Margaret has more than 26 years of industry experience and she has held various positions in corporate strategy, commercial operations, global brand management, business technology, finance, and business consulting.

Most recently, she was with Sanofi, where she led the multi-billion US Diabetes Biologics business which included both basal and meal-time insulins, plus a novel basal/GLP-1 fixed dose combination product.

Prior to Sanofi, she worked for Pfizer, Wyeth, and Arthur Andersen. She has an MBA from Columbia University and a B.S. in accounting from Rutgers University.


Lisa Davidson is Chief Financial Officer of Fractyl. Lisa has more than twenty-five years of broad corporate finance experience encompassing treasury management, strategic planning, operations finance, and controllership.

She served as Vice President of Finance & Administration of Flexion Therapeutics, Inc. Prior to Flexion, Lisa served as Director of Finance at OmniSonics Medical Technologies, Inc.

She previously served in various finance, strategy, and administration positions at PerkinElmer Inc., Pepsi Bottling Group, and Fisher Scientific International, Inc. (now part of ThermoFisher Scientific). Lisa has been involved in a number of M&A transactions, venture debt and equity financings, and numerous product launches. She holds both a B.A. and an MBA from the University of New Hampshire.


Jon Fitzgerald is Vice President of Quality Assurance and Regulatory Affairs at Fractyl. Jon brings more than 20 years of medical device start-up experience to Fractyl.

He has developed and scaled multiple quality systems and has a successful track record of regulatory agency engagement. In addition to his experience in quality, he has successfully conducted recalls, led vigilance activities, and played a pivotal role in global regulatory filings resulting in device clearances and approvals, including the U.S., E.U., Middle East, and Japan.

Previously, Jon held quality engineering and management positions at Neuronetics, Animas (a Johnson & Johnson Company), and Kensey Nash (now DSM Biomedical). His expertise encompasses microbiology, quality management, electronic system implementation, as well as technical file and design dossier development. After serving as an air traffic controller in US Navy, Jon studied mechanical engineering at Northeastern University.


Juan Carlos Lopez-Talavera, M.D., Ph.D. is Chief Medical Officer of Fractyl. Juan Carlos is a pharmaceutical expert in all aspects of research and development with more than 15 years of industry experience, from disease pathogenesis, target identification, pre-clinical and clinical development through to medical affairs for marketed products.  He has published more than 50 peer-reviewed original manuscripts.

Most recently, he served as Chief Medical Officer of Enterome Biosciences, where he led the company’s pipeline and clinical and pre-clinical development programs, clinical regulatory affairs and patient engagement.

Prior to joining Enterome, he held positions of increasing responsibility in large pharma at Intercept Pharmaceuticals, AbbVie, Bristol Myers Squibb, and Roche Laboratories.  He holds an M.D. and a Ph.D. in Hepatology from Universidad Autónoma de Barcelona.


Len Rosberg is Vice President of Manufacturing at Fractyl.

He brings more than twenty years of experience in supply chain management and manufacturing engineering roles for major medical device firms. With more than a decade of senior management expertise, Len most recently served as Vice President of Operations for Candela Corporation, and his industry tenure includes positions at Boston Scientific, Thoratec, and Baxter International.

His technical expertise encompasses reliability engineering, design for manufacturability, and implementation of scalable manufacturing processes. Len holds a B.S. degree in electrical engineering from Wentworth Institute of Technology.

Board of Directors

Allan Will


William W. Bradley

Former U.S. Senator

Brian Dovey

Partner, Domain Associates, LLC

Chris Gabrieli

Partner, Bessemer Venture Partners

Michael L. Huang

Managing Partner, Taiwania Capital Management

Stan Lapidus

President, CEO and Founder of SynapDX

Amy Schulman

Partner, Polaris Partners

Harith Rajagopalan, MD, PhD

Co-Founder and CEO, Fractyl

Ajay Royan

Co-founder and Managing General Partner, Mithril


Allan Will is a seasoned executive with extensive experience founding, funding, operating, and selling medical device companies. He currently also serves as Chairman, President and CEO of EBR Systems and Chairman of the Board for Setpoint Medical.

Most recently, Allan was Founder, Chairman and CEO of The Foundry, an incubator dedicated to transforming medical device concepts into companies, where he co-founded 11 companies, including among others Ardian Inc. and Evalve Inc.

Formerly, Allan was a founding Managing Director in Split Rock Partners’ Silicon Valley venture capital office, focusing on the therapeutic medical device field. Earlier in his career, Allan spent more than 20 years in operating roles in medical device companies, with the last 17 as CEO of various Bay-area venture backed start-ups. Allan currently holds more than 20 issued patents. He earned his M.S. in management at MIT and his B.S. in zoology from the University of Maryland.


Senator William W. Bradley served in the U.S. Senate from 1979 to 1997 representing the state of New Jersey. In 2000, he was a candidate for the Democratic nomination for President of the United States.

Previously, he was chief outside advisor to McKinsey & Company’s nonprofit practice and was a Senior Advisor and Vice Chairman of the International Council of JP Morgan & Co. He has worked as an essayist for CBS Evening News and was a visiting professor at Stanford University, University of Notre Dame, and the University of Maryland. Senator Bradley has authored seven books on American politics, culture and economy, including his latest book We Can All Do Better.

Currently, he hosts American Voices, a weekly show on Sirius XM Satellite Radio that highlights the remarkable accomplishments of Americans both famous and unknown. Prior to serving in the Senate, he was an Olympic gold medalist in 1964 and a professional basketball player with the New York Knicks from 1967 to 1977 during which time they won two NBA championships. In 1982, he was elected to the Basketball Hall of Fame. Senator Bradley holds a B.A. degree in American History from Princeton University and an M.A. degree from Oxford University where he was a Rhodes Scholar.


Brian Dovey has been a partner of Domain since 1988, where he has led innovative investments in life sciences companies. Since joining Domain, he has served on the boards of directors of more than 35 private and public companies and has been chairman of six.

Prior to Domain, Brian was president of Rorer Group, now a part of Sanofi, where he was the primary architect of a strategy transforming the company from a diversified medical products company to a fully integrated pharmaceutical company, doubling sales with a multi-fold increase in profits.

Previous to that, Brian was president of Survival Technology, a start-up medical products company whose sales growth placed it in the top ten of the Inc 100. Brian was formerly chairman and currently serves on the boards of directors of both the Center for Venture Education (Kauffman Fellows Program) and the Wistar Institute, a leader in preclinical bio-medical research in the non-profit sector. He received his B.A. in mathematics from Colgate University and his MBA from Harvard Business School.


Chris Gabrieli, a partner in Bessemer’s Cambridge office, joined the firm in 1986 to launch its healthcare practice.

In 25 years of investing with Bessemer, he has invested broadly in healthcare and other industries. He currently focuses on biotechnology, healthcare services, and education. Prior to his career at Bessemer, Chris founded and served as CEO of GMIS, a healthcare-software company he co-founded and helped build, take public, and sell to the leading industry consolidator, McKesson.

Chris graduated from Harvard University with a B.A. in history and science and completed two years of the Columbia College of Physicians & Surgeons M.D. program. He is also a leader in education innovation and is founder and chairman of the National Center on Time & Learning and a lecturer at the Harvard Graduate School of Education.


Prior to joining Taiwania as founding partner of the life science fund, Michael was the co-founder and CEO of NeuroVive Pharmaceutical Asia, Inc. (NVP Asia), a new drug development company focusing on the development of mitochondria-related diseases. During his tenure, NVP Asia had successfully signed out-licensing deals with Sihuan Pharmaceutical and Sanofi Korea.

Michael had over 18 years of experience as a venture capitalist, focusing on investments and management of early to late-stage biotech and medical device startups in Greater China, Japan, European and North America regions.

Michael received his MBA degree from Rice University Jesse H. Jones Graduate School of Business and his MS degree in Chemistry from University of Texas at Arlington.


Stan Lapidus is an experienced life-science entrepreneur and inventor with more than 30 issued U.S. patents.

He founded SynapDX, a new company developing diagnostic tests for the early detection of autism, and currently serves as President and CEO. Prior to SynapDX, Stan founded and led Cytyc, EXACT Sciences and Helicos BioSciences, and holds academic appointments at Tufts and MIT.

From 2002 to 2012, Stan served as a trustee of Cooper Union, his alma mater. He was recently inducted into the College of Fellows of the American Institute of Medical and Biological Engineering.


Amy Schulman is a healthcare investor and managing partner of the LS Polaris Innovation Fund. She is a highly respected leader in the biotech and pharmaceutical industries. Ms. Schulman joined Polaris Partners in 2014, simultaneously assuming the role of CEO of Arsia Therapeutics, a company acquired by Eagle Pharmaceuticals in 2016. In 2015, Ms. Schulman co-founded Lyndra, where she is CEO. She became CEO and Executive Chair of Olivo Laboratories in 2017, which sold its cosmetic business to Shiseido in 2018, and serves as Executive Chair of SQZ Biotech.

Prior to joining Polaris, Schulman was the general counsel of Pfizer, president of Pfizer Nutrition, and ran Pfizer consumer healthcare after the nutrition business was sold to Nestle in 2012. She is the recipient of numerous awards including: Scientific American’s “2015 Worldview 100 List”, Fierce Biotech’s 2014 “Top 15 Women in Biotech”, and Fortune Magazine’s 2013 “50 Most Powerful Women in Business”.

Amy is a Senior Lecturer at Harvard Business School where she teaches Leadership and Corporate Accountability. She serves on the Board of Directors of Alnylam Pharmaceuticals, Ironwood Pharmaceuticals, and the Whitehead Institute.

She is a Phi Beta Kappa graduate of Wesleyan University and earned her J.D. from Yale Law School.


Dr. Harith Rajagopalan is Co-founder and CEO of Fractyl, having started the company while serving as an Entrepreneur-in-Residence at General Catalyst Partners.

Prior to founding Fractyl, Harith was an academic cardiologist and physician-scientist. He received his B.S. in chemistry from Stanford University and went on to obtain M.D. and Ph.D. degrees from Johns Hopkins School of Medicine. At Johns Hopkins, Harith did groundbreaking and award-winning research on intestinal cancers that was published in top medical journals, including Nature and Science.

After medical school, Harith trained in internal medicine and clinical cardiology at Brigham and Women’s Hospital and completed a research fellowship at Harvard Medical School.


Ajay Royan created and runs Mithril, a growth fund that makes concentrated investments in transformative and durable technology companies around the world.

Ajay and his team partner with innovators building companies in industries as diverse as cybersecurity, advanced medical devices, and fusion energy. Before forming Mithril, Ajay was a member of the core team that grew Clarium Capital into a multibillion-dollar macro fund.

He serves as an external advisor to Oak Ridge National Labs and the University of Michigan Risk Science Center. He was educated at Yale.

Scientific Advisors

Alan Cherrington, Ph.D., Chairman

Professor of Molecular Physiology and Biophysics, Professor of Medicine & Jacquelyn A. Turner and Dr. Dorothy J. Turner Chair in Diabetes Research, Vanderbilt University, Nashville, Tennessee; Past-President of American Diabetes Association

John Amatruda, M.D.

Former Senior Vice President and Franchise Head for Diabetes and Obesity, Merck & Co., New York City, New York

Geltrude Mingrone, M.D., Ph.D.

Chief of the Division of Obesity and Metabolic Diseases & Professor of Medicine at Catholic University, Rome, Italy

Jacques Deviere, M.D., Ph.D.

Professor of Medicine and Chairman of the Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, Erasme University Hospital, Brussels, Belgium

Jacques Bergman, M.D., Ph.D.

Professor of Gastrointestinal Endoscopy, University of Amsterdam’s Faculty of Medicine, Amsterdam, The Netherlands

Christopher Thompson, M.D.

Director of Therapeutic Endoscopy, Brigham and Women’s Hospital; Associate Professor of Medicine, Harvard Medical School, Boston, Massachusetts

Arun J. Sanyal, M.D.

Education Core Director at C. Kenneth and Dianne Wright Center for Clinical and Translational Research & Professor in the gastroenterology division of the Department of Internal Medicine at the Virginia Commonwealth University School of Medicine

Deepak L. Bhatt, M.D., MPH

Executive Director of Interventional Cardiovascular Programs at Brigham and Women's Hospital & Professor of Cardiovascular Medicine at Harvard Medical School

David C. Klonoff, M.D.

Board-certified endocrinologist, Clinical Professor of Medicine at UCSF, Medical Director of the Diabetes Research Institute Mills-Peninsula Medical Center, and Editor-in-Chief, Journal of Diabetes Science and Technology

You are now leaving the website

You are leaving Fractyl’s main website to go to Fractyl’s U.K. site.

By selecting Continue you will be directed to Fractyl’s U.K. site. If you would like to remain on Fractyl’s main site, select the Cancel button.